Monica Balzarotti

Rozzano, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Journal: Blood advances
Published: April 16, 2026

Stem Cell Mobilization and Autologous Transplantation Outcomes After First-Line R-DA-EPOCH in High-Risk DLBCL and HGBCL: A Single-Center Retrospective Study.

Stem Cell Mobilization and Autologous Transplantation Outcomes After First-Line R-DA-EPOCH in High-Risk DLBCL and HGBCL: A Single-Center Retrospective Study.

Journal: Cancers
Published: April 12, 2026

Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial.

Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial.

Journal: HemaSphere
Published: October 10, 2025

Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).

Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).

Journal: British journal of haematology
Published: July 24, 2025

Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study.

Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study.

Journal: The Lancet. Haematology
Published: April 28, 2025

Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphoma.

Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphoma.

Journal: Haematologica
Published: March 15, 2025

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Journal: Blood
Published: February 20, 2025

Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients.

Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients.

Journal: HemaSphere
Published: November 19, 2024

Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial.

Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial.

Journal: Blood advances
Published: September 30, 2024

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 19, 2024

Rolling the DICEP on lymphoma salvage treatments? Choose wisely.

Rolling the DICEP on lymphoma salvage treatments? Choose wisely.

Journal: British journal of haematology
Published: June 21, 2024

IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.

IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.

Journal: Blood advances
Published: July 18, 2023
Showing 1-12 of 56

Last Updated: 09/26/2026